Biosimilars staff at the US Food and Drug Administration will be more directly involved in supplement assessments and see its role grow beyond the advisory and policy development spaces.
The FDA’s Office of Therapeutic Biologics and Biosimilars will assess biosimilar application supplements that need quick decisions, rather than the traditional team within the Office of New Drugs